November 17, 2026 · Blood · DOI: 10.1182/blood.2026035098

Cytokines to modulate CAR T cells.

Listen to this summary

This review examines how cytokines can be built into CAR T cells to overcome poor expansion, persistence, T-cell exhaustion, and immunosuppressive tumor microenvironments that limit current therapy. It traces the progression from early IL-12 approaches (which showed potent local inflammatory activity but risked systemic toxicity) through common γ-chain cytokines (IL-7, IL-15, IL-21) and IL-18, which has shown early clinical activity in hematologic malignancies. The authors conclude that rational cytokine selection for specific disease settings, combined with precise spatial and temporal control via inducible circuits and synthetic receptors, will be needed to balance efficacy against toxicity.

Barbara Savoldo, Claudia Rossig

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play